Biofil Chemicals and Pharmaceuticals Limited has issued a formal intimation to its shareholders holding shares in physical mode, directing them to mandatorily furnish key compliance-related details. The communication, dated May 05, 2026, was filed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is in alignment with the SEBI Master Circular for Registrars to an Issue and Share Transfer Agents dated February 06, 2026.

Regulatory Background

The intimation has been issued in compliance with SEBI Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 06, 2026. As per the regulatory mandate, all holders of physical securities in listed companies are required to provide specific details to the Registrar and Share Transfer Agent (RTA) of the company. The company has highlighted that this update is essential to ensure seamless communication, compliance with regulatory requirements, and proper credit of dividends, if any, directly to shareholders' bank accounts.

Details Required from Physical Shareholders

Physical shareholders are required to submit the following information to the RTA:

• PAN — Permanent Account Number for identity verification
• Choice of Nomination — via Form SH-13, or cancellation/variation via Form SH-14; shareholders may also opt out via Form ISR-3
• Contact Details — postal address with PIN code and mobile number, registerable via Form ISR-1
• Bank Account Details — bank name, branch name, account number, and IFS code, submittable via Form ISR-1
• Specimen Signature — mandatory for all physical folio holders

Consequences of Non-Compliance

Shareholders whose folios do not have PAN, KYC details, and nomination updated will face the following restrictions:

• They will be eligible to lodge grievances or avail any service request from the RTA only after furnishing PAN, KYC details, and nomination.
• With effect from April 01, 2024, any payment including dividend, interest, or redemption payment in respect of such folios will be made only through electronic mode. An intimation will be sent by the company to the security holder that such payment is due and will be made electronically only upon complying with the stated requirements.

Submission Modes

Shareholders may submit the required documents and details through any one of the following modes:

• In Person Verification (IPV): The authorized person of the RTA shall verify original documents and retain copies with IPV stamping, date, and initials.
• Hard copies: Self-attested and dated copies submitted directly.
• Electronic mode: Submission with e-sign, as elaborated under the applicable SEBI circular.

RTA Contact Details

Shareholders are requested to submit the required details to the company's RTA at the earliest. The contact information for the RTA is provided below:

The relevant forms for nomination and updation of PAN/KYC details are available on the company's website as well as on the RTA's website at www.ankitonline.com . The intimation was signed by Apoorv Jain, Company Secretary and Compliance Officer, on behalf of Biofil Chemicals and Pharmaceuticals Limited.

Biofil chemicals and Pharmaceuticals Limited has officially declared its non-applicability under the SEBI Large Corporate framework, confirming that it does not meet the criteria for large entity classification as on March 31, 2026. The company has communicated this status to both BSE Limited and National Stock Exchange of India Limited through a formal disclosure.

Regulatory Compliance Declaration

The company has declared that it does not fall under the Large Corporate category as per SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, as amended from time to time. This circular pertains to fund raising by issuance of debt securities by large entities. Consequently, the requirement of filing disclosures in the specified format under the aforementioned circular is not applicable to the company.

Financial Position Details

As part of the disclosure requirements, the company has provided key financial information in the prescribed format:

Compliance Framework Reference

The company has confirmed its status based on the applicability criteria outlined in Chapter XII of SEBI Operational circular dated August 10, 2021, and further updated on April 13, 2022. The declaration was signed by Apoorv Jain, Company Secretary & Compliance Officer, and Pavan Singh Rajput, Chief Financial Officer, dated April 10, 2026.

Corporate Information

Biofil Chemicals and Pharmaceuticals Limited operates from its registered office at B/12-B, Industrial Estate, Pologround, Indore-452015, Madhya Pradesh. The company maintains its corporate compliance through designated officers and has submitted the required annexure as part of the regulatory disclosure process.